中新集團(601512.SH):擬參與投資蘇州高美雲景二期創業投資合夥企業
格隆匯6月6日丨中新集團(601512.SH)公佈,公司擬作為有限合夥人以自有資金不超過1,000萬元參與投資標的基金,主要對新一代信息技術(如:人工智能+、數字智能+、機器智能+等科技項目)領域的企業進行投資。本基金於2023年7月12日完成工商註冊。標的基金擬主要引進多家機構投資者,目標規模不低於1億元、不超過1.5億元,最終以實際募集情況為準。公司擬認繳出資不超過1,000萬元,且佔比不超過最終基金認繳總額的10%。投資標的名稱:蘇州高美雲景二期創業投資合夥企業(有限合夥)(簡稱“高美二期基金”、“標的基金”或“本基金”)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.